Drug Discovery

Summit signs deal with Eurofarma for Latin American rights to Ridinilazole

Summit Therapeutics has entered into an exclusive licence and commercialization agreement with Eurofarma Laboratórios, granting rights in Latin America to Summit's precision antibiotic ridinilazole in development for the treatment of CDI.

vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei

vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.

MilliporeSigma signs commercial supply agreement with bluebird bio for viral vector manufacturing

MilliporeSigma has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for use in potentially transformative gene therapies.

Cancer Research UK, Celgene to collaborate on new anti-cancer treatments

Cancer Research Technology (CRT), a subsidiary of Cancer Research UK, has entered into collaboration with American biopharmaceutical firm Celgene for the discovery, development and commercialization of new anti-cancer treatments.

Asklepios BioPharmaceutical launches new portfolio company Actus Therapeutics

Asklepios BioPharmaceutical has formed Actus Therapeutics, a new portfolio company based on AskBio’s industry-leading gene therapy platform.

Aerogen Pharma, Lyomark Pharma to develop inhaled surfactant

Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.

Report expects global cryotherapy market to cross $4bn by 2024

A new report from Persistence Market Research expects worldwide cryotherapy market to exceed $4bn by 2024.

bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy

bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.

Gilead Sciences to acquire Cell Design Labs in $567m deal

Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.